Stockreport

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye...

Aldeyra Therapeutics, Inc.  (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
PDF Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and =10 mm Schirmer Test Responder Proportions (pTRANQUI [Read more]